Search

Natera Inc

Geschlossen

BrancheGesundheitswesen

338.44 0.56

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

335.16

Max

342.62

Schlüsselkennzahlen

By Trading Economics

Einkommen

18M

-67M

Verkäufe

56M

753M

EPS

-0.47

Gewinnspanne

-8.897

Angestellte

6,135

EBITDA

20M

-45M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

-0.93% downside

Dividenden

By Acuity

Nächstes Ergebnis

5. Nov. 2026

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

8.5B

47B

Vorheriger Eröffnungskurs

337.88

Vorheriger Schlusskurs

338.44

Nachrichtenstimmung

By Acuity

23%

77%

63 / 340 Ranking in Healthcare

Natera Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

26. Aug. 2026, 19:26 UTC

Natera Inc's shares are higher today, reflecting a general market uptrend. The stock remains above its 20-day moving average and near a one-month high.

24. Aug. 2026, 19:46 UTC

Natera Inc shares are lower today, pulling back from earlier session highs. Rising oil prices and geopolitical tensions impact overall market sentiment.

21. Aug. 2026, 20:06 UTC

Natera Inc shares are higher today, rebounding from an early dip amid positive momentum in the biotechnology sector and overall market performance.

20. Aug. 2026, 23:16 UTC

Natera Inc. shares are slightly higher in after-market hours, remaining near the upper end of their one-month range amid broader market pressure from rising yields.

19. Aug. 2026, 20:02 UTC

Natera Inc shares are higher today amid a broader market rally, with notably increased trading volume indicating heightened investor interest.

18. Aug. 2026, 23:36 UTC

Natera Inc shares are lower in after-market hours, with no specific news identified. Broader market sentiment is impacted by declines in the Nikkei 225 Index.

17. Aug. 2026, 19:36 UTC

Social Media
News

Natera Inc reports second-quarter revenue of $752.8 million, exceeding expectations. Shares are higher as the company cites strong test volume growth and regulatory approvals.

13. Aug. 2026, 19:26 UTC

News
Event

Natera Inc is trading lower despite announcing a collaboration on a Phase 1 clinical trial and exceeding second-quarter expectations by $100 million.

12. Aug. 2026, 20:06 UTC

News
Event

Natera Inc shares are rising after analyst upgrades and support for a Phase 1 trial in Germany using its Latitude assay to monitor tumor DNA.

11. Aug. 2026, 20:02 UTC

News

Natera Inc reported strong Q2 revenue of $752.8 million but shares are lower amid concerns over significant insider selling.

10. Aug. 2026, 20:02 UTC

News
Social Media

Natera Inc shares are lower amid negative sentiment from insider selling, despite recent analyst upgrades and price target increases from Morgan Stanley and Barclays.

7. Aug. 2026, 20:03 UTC

Social Media
News

Natera Inc. shares rise sharply after analyst upgrades and strong earnings. RBC Capital raised its price target to $350, citing robust revenue growth.

6. Aug. 2026, 23:02 UTC

Social Media
News

Natera Inc reported second-quarter revenue of $752.8 million, exceeding expectations. The stock is trading higher after the market closed, following strong earnings results.

5. Aug. 2026, 23:01 UTC

Event

Natera Inc announced an application for the Signatera test in Japan. Shares are trading lower in after-market hours following the announcement.

4. Aug. 2026, 19:04 UTC

Natera Inc shares are rising amid a broader market rally and high trading volume, despite challenges from declining U.S. factory orders and falling oil prices.

3. Aug. 2026, 19:23 UTC

News

Natera Inc. shares are higher today, reflecting broader market gains amid strong manufacturing data and significant increases in major technology stocks.

31. Juli 2026, 19:46 UTC

Social Media

Natera Inc shares are lower today, reflecting broader declines in the genomic sector despite earlier gains and a rebound through key moving averages.

30. Juli 2026, 17:51 UTC

News

Citi initiated coverage of Natera Inc with a Buy rating and a $300 price target, contributing to the stock's upward movement today.

29. Juli 2026, 22:02 UTC

Natera Inc. shares declined in after-market trading, reversing an initial uptick. The stock is below its 20-day moving average amid cautious market sentiment.

28. Juli 2026, 23:46 UTC

Natera Inc shares are higher in after-market hours, showing positive momentum despite remaining below their 20-day moving average after recent declines.

27. Juli 2026, 19:46 UTC

News

Natera Inc's shares are lower today, reflecting broader market trends amid a significant drop in crude oil prices affecting sentiment across sectors.

24. Juli 2026, 18:46 UTC

News

Natera Inc's shares are lower, retracing from earlier highs amid broader market dynamics and a drop in oil prices affecting various sectors.

22. Juli 2026, 18:36 UTC

News

Natera Inc shares are lower following a JAMA study showing its Signatera test's effectiveness for Merkel cell carcinoma, despite favorable sensitivity results.

21. Juli 2026, 18:36 UTC

Natera Inc shares are higher, reflecting positive sentiment in U.S. markets amid strong earnings from companies like General Motors and Novartis.

20. Juli 2026, 18:16 UTC

News

Natera Inc. shares are lower today, despite positive developments expanding access to its Prospera transplant test and increased revenue from higher testing volumes.

Peer-Vergleich

Kursveränderung

Natera Inc Prognose

Kursziel

By TipRanks

-0.93% Nachteil

12-Monats-Prognose

Durchschnitt 335.29 USD  -0.93%

Hoch 375 USD

Tief 260 USD

Basierend auf 21 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Natera Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

21 ratings

19

Buy

2

Halten

0

Sell

Stimmung

By Acuity

63 / 340 Ranking in Gesundheitswesen

Nachrichtenstimmung

Sehr starke bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Überdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Natera Inc

Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was founded in 2003 and is headquartered in Austin, Texas.
help-icon Live chat